Hikma Pharmaceuticals (HIK) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition adds commercialized products and a pipeline of 10 ready-to-use injectable products, supporting growth and high margins in the injectables division.

• Diversifies and enriches the US injectables portfolio, adding complex manufacturing technologies and expanding specialty product offerings.

• Provides a large manufacturing facility with advanced lyophilization technology and a well-established R&D center in Croatia, enhancing both capacity and innovation.

• Facility location in the US reduces shipping costs and improves market responsiveness for bulky injectable products.

• CEO and Injectables President highlight the deal's value in scaling US operations and serving hospital and patient needs.

Financial terms and conditions

• Cash consideration of $135 million, with up to $50 million in contingent payments tied to regulatory and commercial milestones.

• Immediate annualized revenue contribution of $75 million from acquired in-market products.

• Neutral to core earnings in the first 12 months post-closing, accretive thereafter.

• Acquisition reduces anticipated capital expenditure for the base business by redirecting investment to the new site.

• Includes contingent milestone payments tied to sales of a specific product.

Synergies and expected cost savings

• Significant expansion of manufacturing capacity, with the Cleveland facility expected to increase injectables output after a two- to three-year enhancement project.

• Manufacturing synergies expected as products are transferred in-house, improving margins over the medium term.

• Automation and process redesign at the new facility will drive efficiency and cost savings.

• US-based production lowers logistics costs compared to shipping from Europe.

• Potential to leverage the facility for contract manufacturing and improved productivity.